.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,734,833

« Back to Dashboard

Claims for Patent: 8,734,833

Title:Therapeutic foam
Abstract: A therapeutic foam for the treatment of, inter alia, varicose veins comprises a sclerosing solution foamed with a physiological gas such as carbon dioxide, oxygen or a mixture thereof. The foam has a nitrogen content of less than 0.8%. It may be generated using a pressurized canister system incorporating a fine mesh of micron dimensions through which the gas and sclerosing liquid are passed to make the foam. Alternatively, the foam may be generated by passing gas and solution between two syringes through a fine mesh. Techniques are described for minimizing the amount of nitrogen in a canister or syringe based product. A technique for generating and delivering foam simultaneously using a syringe based device is also disclosed.
Inventor(s): Wright; David Dakin Iorwerth (Henley on Thames, GB), Harman; Anthony David (Henley on Thames, GB), Robinson; Nikki (Newmachar, GB), Hodges; Garry (Welwyn, GB), Kadar; Adil (London, GB), Moggridge; Geoffrey D. (Cambridge, GB), Liew; Hugh Van (Barnstable, MA)
Assignee: BTG International Ltd. (GB)
Application Number:13/667,296
Patent Claims: 1. A foam comprising a liquid phase and a gas phase wherein the liquid phase comprises at least one sclerosing agent and the gas phase consists essentially of 0.01% to 0.8% vol/vol nitrogen, 10% to 99.99% vol/vol carbon dioxide, and the remaining gas, if any, consisting essentially of oxygen.

2. The foam of claim 1, wherein the nitrogen is present in an amount ranging from 0.01% to 0.7%.

3. The foam of claim 1, wherein the nitrogen is present in an amount ranging from 0.01% to 0.6%.

4. The foam of claim 1, wherein the foam has a density of less than 0.25 g/ml and a half life of greater than 100 secs.

5. The foam of claim 1, wherein the foam has a half of at least 120 seconds.

6. The foam of claim 1, wherein the foam has a half life of at least 150 seconds.

7. The foam of claim 1, wherein the foam has a half life of at least 180 seconds.

8. The foam of claim 1, wherein the foam has a density ranging from 0.07 to 0.22 g/ml.

9. The foam of claim 1, wherein the foam has a density ranging from 0.07 to 0.19 g/ml.

10. The foam of claim 1, wherein the foam has a density ranging from 0.07 to 0.16 g/ml.

11. The foam of claim 1, wherein the foam has a density ranging from 0.08 to 0.14 g/ml.

12. The foam of claim 1, wherein the at least one sclerosing agent is chosen from polidocanol, glycerol and sodium tetradecyl sulphate.

13. The foam of claim 1, wherein the at least one sclerosing agent is polidocanol.

14. The foam of claim 13, wherein the polidocanol is present in a concentration ranging from 0.5% to 4% vol/vol in the liquid phase.

15. A foam comprising: a liquid phase and a gas phase, wherein the liquid phase comprises at least one sclerosing agent; and the gas phase consists essentially of 0.01% to 0.8% vol/vol nitrogen, about 10% to about 99.99% vol/vol carbon dioxide, and the remaining gas, if any, consisting essentially of oxygen.

16. The foam of claim 15, wherein the nitrogen is present in an amount ranging from 0.01% to 0.7%.

17. The foam of claim 15, wherein the nitrogen is present in an amount ranging from 0.01% to 0.6%.

18. The foam of claim 15, wherein the foam has a density of less than 0.25 g/ml and a half life of greater than 100 secs.

19. The foam of claim 15, wherein the foam has a half life of at least 120 seconds.

20. The foam of claim 15, wherein the foam has a half life of at least 150 seconds.

21. The foam of claim 15, wherein the foam has a half life of at least 180 seconds.

22. The foam of claim 15, wherein the foam has a density ranging from 0.07 to 0.22 g/ml.

23. The foam of claim 15, wherein the foam has a density ranging from 0.07 to 0.19 g/ml.

24. The foam of claim 15, wherein the foam has a density ranging from 0.07 to 0.16 g/ml.

25. The foam of claim 15, wherein the foam has a density ranging from 0.08 to 0.14 g/ml.

26. The foam of claim 15, wherein the at least one sclerosing agent is chosen from polidocanol, glycerol and sodium tetradecyl sulphate.

27. The foam of claim 15, wherein the at least one sclerosing agent is polidocanol.

28. The foam of claim 27, wherein the polidocanol is present in a concentration ranging from 0.5% to 4% vol/vol in the liquid phase.

29. A foam comprising: a liquid phase and a gas phase, wherein the liquid phase comprises at least one sclerosing agent; and the gas phase consists essentially of 0.01% to 0.8% vol/vol nitrogen, at least 50% vol/vol carbon dioxide, and the remaining gas, if any, consisting essentially of oxygen.

30. The foam of claim 29, wherein the nitrogen is present in an amount ranging from 0.01% to 0.7%.

31. The foam of claim 29, wherein the nitrogen is present in an amount ranging from 0.01% to 0.6%.

32. The foam of claim 29, wherein the foam has a density of less than 0.25 g/ml and a half life of greater than 100 secs.

33. The foam of claim 29, wherein the foam has a half life of at least 120 seconds.

34. The foam of claim 29, wherein the foam has a half life of at east 150 seconds.

35. The foam of claim 29, wherein the foam has a half life of at least 180 seconds.

36. The foam of claim 29, wherein the foam has a density ranging from 0.07 to 0.22 g/ml.

37. The foam of claim 29, wherein the foam has a density ranging from 0.07 to 0.19 g/ml.

38. The foam of claim 29, wherein the foam has a density ranging from 0.07 to 0.16 g/ml.

39. The foam of claim 29, wherein the foam has a density ranging from 0.08 to 0.14 g/ml.

40. The foam of claim 29, wherein the at least one sclerosing agent is chosen from polidocanol, glycerol and sodium tetradecyl sulphate.

41. The foam of claim 29, wherein the at least one sclerosing agent is polidocanol.

42. The foam of claim 41, wherein the polidocanol is present in a concentration ranging from 0.5% to 4% vol/vol in the liquid phase.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc